Anti-Angiogenic Gene Therapy for Prostate Cancer
Annual rept. 1 Apr 2004-31 Mar 2005
ALABAMA UNIV IN BIRMINGHAM
Pagination or Media Count:
During the last funding period, we produced high-titer recombinant AAV vectors encoding mouse endostatin and angiostatin, and human osteoprotegerin, established TRAMP mouse breeding colony, and initiated in vivo studies to determine the effects of anti-angiogenic therapy at two different stages of prostate cancer progression. Additionally, we constructed rAAV encoding human OPG, produced high-titer virus and validated the biological efficacy of the vector encoded protein in inhibiting osteoclastogenesis in vitro. Continuation of the ongoing studies in to next year will provide valuable information on therapeutic effects of anti-angiogenic gene therapy using adeno-associated virus in prostate cancer growth and metastasis.
- Medicine and Medical Research